ELTP — Elite Pharmaceuticals Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousSmall CapContrarian

Annual income statement for Elite Pharmaceuticals, fiscal year end - March 31st, USD millions except per share, conversion factor applied.

	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st	2026 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	32.3	34.2	56.6	84	149
Cost of Revenue
Gross Profit	14.8	16.6	26.4	40.1	75
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	27.2	30.5	44.1	64.4	99.8
Operating Profit	5.07	3.68	12.6	19.6	49.1
Total Net Non Operating Interest Income / Expense
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	6.3	3.99	0.463	-0.052	56.8
Provision for Income Taxes
Net Income After Taxes	8.04	3.56	20.1	-4.31	44.9
Net Income Before Extraordinary Items
Net Income	8.04	3.56	20.1	-4.31	44.9
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	8.9	3.56	20.1	-4.31	44.9
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.009	0.003	0.019	-0.003	0.04